X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

    Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

    Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

    Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

    Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre

    INOVIO to Develop dMAb COVID Treatments under DARPA Grant

    Thermo Fisher Scientific Launches Modular Closed Cell Processing System for Cell Therapy Manufacturing

    Thermo Fisher Expands Clinical Supply Services in Europe

    Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine

    Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine

    U.S. FDA confirms Pfizer COVID vaccine safe & effective

    U.S. FDA confirms Pfizer COVID vaccine safe & effective

    Abzena Invests $60M Into cGMP Manufacturing Capacity

    COVID-19 Vaccine – Has UK created the pressure to rush on other countries?

    The UK begins the biggest ever immunization program

    The UK begins the biggest ever immunization program

    Russia roll out the homegrown Sputnik V vaccine for its population

    Russia roll out the homegrown Sputnik V vaccine for its population

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

    Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

    Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

    Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

    Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre

    INOVIO to Develop dMAb COVID Treatments under DARPA Grant

    Thermo Fisher Scientific Launches Modular Closed Cell Processing System for Cell Therapy Manufacturing

    Thermo Fisher Expands Clinical Supply Services in Europe

    Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine

    Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine

    U.S. FDA confirms Pfizer COVID vaccine safe & effective

    U.S. FDA confirms Pfizer COVID vaccine safe & effective

    Abzena Invests $60M Into cGMP Manufacturing Capacity

    COVID-19 Vaccine – Has UK created the pressure to rush on other countries?

    The UK begins the biggest ever immunization program

    The UK begins the biggest ever immunization program

    Russia roll out the homegrown Sputnik V vaccine for its population

    Russia roll out the homegrown Sputnik V vaccine for its population

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine

Content Team by Content Team
20th July 2020
in Drug Development, Featured, Manufacturing, News
GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine

GSK and Medicago announced a collaboration to develop and evaluate a COVID-19 candidate vaccine combining Medicago’s recombinant Coronavirus Virus-Like Particles (CoVLP) with GSK’s pandemic adjuvant system. CoVLPs mimic the structure of the virus responsible for COVID-19 disease, allowing them to be recognised by the immune system. Use of an adjuvant can be of particular importance in a pandemic situation as it may boost the immune response and reduce the amount of antigen required per dose, allowing more vaccine doses to be produced and therefore contributing to protect more people.

Pre-clinical results with Medicago’s CoVLP vaccine candidate demonstrated a high level of neutralizing antibodies following a single dose when administered with adjuvant.

Phase 1 clinical testing is planned to start in mid-July and will evaluate the safety and immunogenicity of three different dose levels of antigen combined with GSKs pandemic adjuvant and in parallel with an adjuvant from another company, administered on a one- and two-dose vaccination schedule, given 21 days apart.

Subject to successful clinical development and regulatory considerations, the companies aim to complete development and make the vaccine available, in the first half of 2021. Both companies will also evaluate expanding their collaboration to develop a post-pandemic vaccine COVID-19 candidate, should the need arise based on the further development of COVID-19 after the pandemic, and other infectious diseases.

The companies will use Medicago’s plant-based production platform to manufacture the COVID-19 vaccine antigen. This innovative technology uses the leaves of a plant as bioreactors to produce the S-spike protein which self-assemble into VLPs for use in the CoVLP vaccine candidate. It is highly scalable and can support the production of large amounts of vaccine in a significantly shortened timeline. Using this technology combined with GSKs proprietary adjuvant system, the companies expect to be able to manufacture approximately 100m doses by the end of 2021. By the end of 2023, a large-scale facility under construction in Quebec City, Canada, is expected to deliver up to 1 billion doses annually. The manufacturing platform has been used to produce a seasonal VLP flu vaccine and the license application is under review with the Canadian regulatory authority.

Dr Thomas Breuer, Chief Medical Officer, GSK Vaccines, said: “This agreement paves the way for an innovative vaccine option combining a scalable plant-based antigen technology with an adjuvant which has pandemic dose sparing capability. If successful, it will be a meaningful contributor in the fight against COVID-19. We strongly believe that multiple vaccines are needed, including post-pandemic vaccines. This plant-based technology also shows promise beyond COVID-19 and has the potential to help prevent other infectious diseases.”

Dr Bruce Clark, President and CEO of Medicago, said: “We are about to begin clinical trials with our CoVLP vaccine candidate harnessing GSKs pandemic adjuvant technology against the virus that causes COVID-19. This collaboration with GSK gives us access to a proven adjuvant which could enhance the effectiveness of our candidate vaccine, and also to a depth of scientific experience to support our development efforts.”

GSK and Medicago have entered into a binding agreement to develop and manufacture an adjuvanted COVID-19 vaccine. Medicago is a privately held company jointly owned by Mitsubishi Tanabe Pharma (MTPC) and Philip Morris International (PMI), with a shareholding ratio of 67:33, respectively. PMI has signalled that it is willing to evaluate offers for its shareholding from parties that may be better suited to help Medicago on the next phase of its journey and has initiated preliminary review to determine the optimal shareholding and governance structure for Medicago’s future success.

About Medicago

Medicago is a biopharmaceutical company headquartered in Quebec City, Canada. Medicago’s mission is to improve global health outcomes by leveraging innovative plant-based technologies for rapid responses to emerging global health challenges. Medicago is committed to advancing therapeutics against life-threatening diseases worldwide.

About GSK

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

Previous Post

Sanofi and MD Anderson announce strategic collaboration to accelerate oncology research and development

Next Post

GSK and CureVac announce strategic mRNA technology collaboration

Related Posts

Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021
News

Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

17th December 2020
Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity
Drug Development

Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

17th December 2020
Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery
Drug Development

Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

17th December 2020
Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre
Drug Development

INOVIO to Develop dMAb COVID Treatments under DARPA Grant

17th December 2020
Thermo Fisher Scientific Launches Modular Closed Cell Processing System for Cell Therapy Manufacturing
Clinical Trials

Thermo Fisher Expands Clinical Supply Services in Europe

17th December 2020
Takeda
News

AstraZeneca and J&J COVID-19 Shots Crucial To Meet US Vaccination Goal

14th December 2020
Next Post
Braun Prefilled Syringe

GSK and CureVac announce strategic mRNA technology collaboration

Latest News

Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021
News

Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

17th December 2020
Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity
Drug Development

Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

17th December 2020
Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery
Drug Development

Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

17th December 2020
Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre
Drug Development

INOVIO to Develop dMAb COVID Treatments under DARPA Grant

17th December 2020
Thermo Fisher Scientific Launches Modular Closed Cell Processing System for Cell Therapy Manufacturing
Clinical Trials

Thermo Fisher Expands Clinical Supply Services in Europe

17th December 2020
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In